Suven Life Sciences Ltd’s Alzheimer Drug Candidate SUVN-502 Successfully Completed All Chronic Toxicological (tox) Studies and Demonstrated Very High Margin of Safety (MOS)

HYDERABAD, INDIA (May 18, 2011) – Suven Life Sciences Ltd (Suven) announces today that their clinical drug candidate SUVN-502 completed all the long term chronic studies like 6-month rat tox, 9-month dog tox and developmental tox studies like prenatal development tox in rats and rabbits, embryo-fetal development tox in rats and male fertility tox in rats very successfully and demonstrated very high margin of safety (MOS). These regulatory tox studies are essential for FDA approval to initiate human phase 2a clinical trials in patient population.

SUVN-502 has been tested in human Phase 1 trials in Switzerland and demonstrated to be very safe at all doses and durations tested with excellent bioavailability. The next stage of testing will be proof of concept Phase 2 a clinical trials in patients with Alzheimer’s / Schizophrenia disease.

"We are very pleased with the excellent outcome of all chronic and developmental tox studies for our clinical candidate SUVN-502 which is being developed for CNS disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia and the potential market opportunity is more than $20 billion globally says Venkat Jasti CEO of Suven Life Sciences.

We have received several interests for SUVN-502 from pharmaceutical companies and anticipate probable partnering in the near future. Simultaneously we are actively engaged to file an Investigational New Drug application (IND) with the US FDA to support initiation of phase 2 a Proof of Concept (PoC) clinical trials in human patients during this year using this tox data.

For more information on Suven, please visit our Web site at www.suven.com